89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks by Carolyn Helms | Mar 22, 2023 | Portfolio News
Somatus Expands Partnership with Inova to Further Enhance Care and Improve Outcomes for Patients by Carolyn Helms | Mar 9, 2023 | Portfolio News
Avenge Bio Receives Positive Feedback from Pre-IND FDA Meeting on Development Path for AVB-001 Mesothelioma Program and Provides Pipeline Update by Carolyn Helms | Mar 9, 2023 | Portfolio News
Ceribell Named to Fast Company’s 2023 List of the World’s Most Innovative Companies by Carolyn Helms | Mar 2, 2023 | Portfolio News
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants by Carolyn Helms | Feb 21, 2023 | Portfolio News
